Korea SPAC 2 (206400) - Total Liabilities
Based on the latest financial reports, Korea SPAC 2 (206400) has total liabilities worth ₩5.85 Billion KRW (≈ $3.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Korea SPAC 2 (206400) long-term investment share to see how much of total assets are deployed in long-term investments.
Korea SPAC 2 - Total Liabilities Trend (2015–2025)
This chart illustrates how Korea SPAC 2's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Korea SPAC 2 assets under control.
Korea SPAC 2 Competitors by Total Liabilities
The table below lists competitors of Korea SPAC 2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wicaksana Overseas International
JK:WICO
|
Indonesia | Rp386.32 Billion |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
USA | $75.94 Million |
|
Iflex Flexible Packaging, S.A.
MC:IFLEX
|
Spain | €5.39 Million |
|
Primech Holdings Ltd. Ordinary Shares
NASDAQ:PMEC
|
USA | $30.00 Million |
|
Drillcon AB
ST:DRIL
|
Sweden | Skr266.49 Million |
|
Netel Holding AB
ST:NETEL
|
Sweden | Skr1.78 Billion |
|
Korea Information Engineering Services Co. Ltd
KQ:039740
|
Korea | ₩69.38 Billion |
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
USA | $9.08 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Korea SPAC 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 206400 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Korea SPAC 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Korea SPAC 2 (2015–2025)
The table below shows the annual total liabilities of Korea SPAC 2 from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩7.09 Billion ≈ $4.80 Million |
-25.63% |
| 2024-12-31 | ₩9.53 Billion ≈ $6.46 Million |
-77.87% |
| 2023-12-31 | ₩43.06 Billion ≈ $29.18 Million |
+37.37% |
| 2022-12-31 | ₩31.35 Billion ≈ $21.24 Million |
-30.63% |
| 2021-12-31 | ₩45.19 Billion ≈ $30.62 Million |
+93.55% |
| 2020-12-31 | ₩23.35 Billion ≈ $15.82 Million |
+122.88% |
| 2019-12-31 | ₩10.47 Billion ≈ $7.10 Million |
-41.79% |
| 2018-12-31 | ₩18.00 Billion ≈ $12.20 Million |
+298.54% |
| 2017-12-31 | ₩4.52 Billion ≈ $3.06 Million |
+29.07% |
| 2016-12-31 | ₩3.50 Billion ≈ $2.37 Million |
+17.66% |
| 2015-12-31 | ₩2.97 Billion ≈ $2.01 Million |
-- |
About Korea SPAC 2
BENO TNR, Inc. engages in interior design, construction, robot, and bio businesses. It engages in the designing, manufacturing, and construction of shading systems, eco-friendly flooring, and radiant heating panels applied to various buildings. It also provides XoMotion, an exoskeleton wearable robot that supports lower body movements; and develops medicine through epigenetic modification. BENO T… Read more